|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/07/23 Cosmos Health Inc. 8-K:5,9 2/01/23 13:165K Discount Edgar/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 27K 2: EX-99.1 Press Release HTML 13K 8: R1 Cover HTML 46K 11: XML IDEA XML File -- Filing Summary XML 12K 9: XML XBRL Instance -- cosm_8k_htm XML 15K 10: EXCEL IDEA Workbook of Financial Reports XLSX 8K 5: EX-101.CAL XBRL Calculations -- cosm-20230201_cal XML 8K 7: EX-101.DEF XBRL Definitions -- cosm-20230201_def XML 11K 4: EX-101.LAB XBRL Labels -- cosm-20230201_lab XML 43K 6: EX-101.PRE XBRL Presentations -- cosm-20230201_pre XML 29K 3: EX-101.SCH XBRL Schema -- cosm-20230201 XSD 19K 12: JSON XBRL Instance as JSON Data -- MetaLinks 12± 17K 13: ZIP XBRL Zipped Folder -- 0001477932-23-000799-xbrl Zip 19K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM i 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) i February 1, 2023
i Cosmos Health Inc. |
(Exact name of registrant as specified in its charter) |
i Nevada |
|
| i 27-0611758 | |
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (I.R.S. Employer Identification No.) |
i 141 West Jackson Blvd, Suite 4236, i Chicago, i Illinois |
| i 60604 |
(Address of principal executive offices) |
| (Zip Code) |
Registrant’s telephone number, including area code ( i 312) i 865-0026
Cosmos Health Inc.
(Former name or former address, if changed since last report.)
Title of Each Class |
| Trading Symbol |
| Name of Each Exchange On Which Registered |
i Common Stock, $.001 par value |
| i COSM |
| i Nasdaq Capital Market |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
i ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
i ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
i ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
i ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b of this chapter).
Emerging growth company i ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 1, 2023, Cosmos Health Inc. (the “Company”) announced the appointment of Nikos Bardakis (54), who comes with over two decades of international branded pharmaceutical sector experience, as the Chief Operating Officer (COO).
As the Chief Operating Officer at Cosmos Health, Mr. Bardakis’ objective will be to bring new capabilities and processes into the organization for optimizing operational excellence towards global commercial expansion of Cosmos’ premium products. In addition, Mr. Bardakis will focus on life science research ideas and transforming them into product innovations that will be designed, engineered, and marketed by Cosmos.
From January 2019 to February 2023, he served as Business Development Manager at Cloudpharm, a research and development company focused on the discovery of bioactive compounds and next generation food supplements, and the development of state-of-the-art algorithms for drug repurposing and providing computational services for drug design and development. From June 2016 to February 2023, Mr. Bardakis was Managing Director of Life NLB, an importing and distributing company specialized in the areas of medical devices and food supplements. From January 2009 to February 2016, Mr. Bardakis was the National Sales Director for Servier Hellas, a multinational pharmaceutical company specializing in the areas of Cardiovascular, Central Nervous System and Metabolic diseases, where he led a cross functional, client focused team comprised of sales, trade, marketing and business development personnel, managing over 130 employees. He gained international exposure, participating in several boards and meetings focused on European level design and launch projects, pioneering in international operations. From 1993 to December 2008, Mr. Bardakis was a sales representative, area manager, full sales manager for Servier Hellas, where he last led seventy (70) representatives and nine (9) area managers. Mr. Bardakis received a BS in Finance from American College of Greece along with relevant studies in Natural Sciences.
Nikos Bardakis will succeed Pavlos Ignatiades, who will assume the position of Chief Communications Officer (CCO). As the Chief Communications Officer at Cosmos Health, Pavlos Ignatiades’ focus will be to create a consistent message across all stakeholders that clearly communicates the Company’s progress, its vision for the future and the roadmap of how it intends to get there. Mr. Ignatiades has been with Cosmos since its inception and was promoted to COO in 2020, where he was responsible for capital markets activities including the Company’s listing onto Nasdaq, as well as managing the Company’s public relations and investor relations departments.
A copy of the press release titled “Cosmos Health Announces the Appointment of Nikos Bardakis, an Experienced Executive in the Pharmaceutical Industry, as Chief Operating Officer” is furnished as Exhibit 99.1 to this Report.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits
Number |
|
|
| ||
104 |
| Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
COSMOS HEALTH INC. | |||
| |||
Date: February 7, 2023 | By: | /s/ George Terzis | |
| |||
Chief Financial Officer |
| ||
| 3 |
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 2/7/23 | None on these Dates | ||
| For Period end: | 2/1/23 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/29/24 Cosmos Health Inc. 424B3 1:333K Discount Edgar/FA 2/15/24 Cosmos Health Inc. 424B3 1:163K Discount Edgar/FA 1/29/24 Cosmos Health Inc. S-3 4:460K Discount Edgar/FA 8/31/23 Cosmos Health Inc. 424B3 1:185K Discount Edgar/FA 8/18/23 Cosmos Health Inc. S-3 4:521K Discount Edgar/FA |